6人の患者の慢性的な再発性クロストリジウムディフィシル性下痢に対する細菌療法
1Department of Clinical Microbiology, Rigshospitalet, Statens Seruminstitut, Denmark.
Lancet (London, England)
|May 27, 1989
まとめ
有益な腸内細菌,特に Bacteroides 種を回復させることで,Clostridium difficileによって引き起こされる慢性下痢を効果的に治療することができます. この糞便の微生物群移植アプローチは,健康な腸内微生物群を再建し,再発するC. difficile感染症を予防します.
科学分野:
- 微生物学 微生物学とは
- 胃腸内科 胃腸内科
- 感染症 感染症は感染症です.
背景:
- 慢性的な再発性下痢は,しばしばClostridium difficile感染によって引き起こされます.
- 特定の腸内細菌が,C. difficileの再発を予防する役割は,十分に理解されていません.
研究 の 目的:
- 慢性的な再発性Clostridium difficile下痢の治療における糞便微生物群移植の有効性を調査する.
- 治療効果に関与する特定の細菌種を特定する.
主な方法:
- 6人の患者で,同類の便または定義された細菌の混合物を直腸内挿入.
- クロストリジウム・ディフィシル,その毒素,および治療前のおよび後の細菌組成に関する便の分析.
- バクテリアの相互作用を評価するためのインビトロ研究.
主要な成果:
- バクテリアの混合物による治療は,C. difficileとその毒素の迅速な排除につながりました.
- 治療後,バクテロイドス種による kolonization が成功していることが観察されました.
- 実験室内試験では,特定の細菌がC. difficileの成長に阻害効果を発揮することを示した.
結論:
- バクテロイド種の不在は,個人を慢性的な再発性C. difficile下痢に誘発する可能性があります.
- 糞便の微生物群移植によるバクテロイドス種の回復は,C. difficileのコロニー化と再発を防ぐことができます.
さらに関連する動画
関連する概念動画
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Microbiota Modulation by Antibiotics
Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...